IDDM2/insulin VNTR modifies risk conferred by IDDM1/HLA for development of Type 1 diabetes and associated autoimmunityMelanie Walter, Ezio Bonifacio, John A. Todd et al.|Diabetologia|2003Cited by 108
Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive ProteinAudrey Y. Chu, Paul M. Ridker, Daniel I. Chasman et al.|Circulation Cardiovascular Genetics|2012Cited by 48
Genome-Wide Association Study Evaluating Lipoprotein-Associated Phospholipase A <sub>2</sub> Mass and Activity at Baseline and After Rosuvastatin TherapyAudrey Y. Chu, Paul M. Ridker, Christie M. Ballantyne et al.|Circulation Cardiovascular Genetics|2012Cited by 41
Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein–Related MeasuresAudrey Y. Chu, Daniel I. Chasman, Franco Giulianini et al.|Circulation Cardiovascular Genetics|2015Cited by 9
Abstract P221: Genome-wide Association Study Evaluating Genetic Determinants of Rosuvastatin Effects on Lp-PLA <sub>2</sub> Mass and ActivityAudrey Y. Chu, Paul M. Ridker, Franco Guilianini et al.|Circulation|2012Cited by 0